Compare ADMA Biologics Inc (ADMA) vs iShares MSCI United Kingdom (FTSE) (EWU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs iShares MSCI United Kingdom (FTSE) — how do they compare? ADMA Biologics Inc trades at $9.87 (market cap $2.22B), while iShares MSCI United Kingdom (FTSE) trades at $48.34. The key difference: iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | EWU | |
|---|---|---|
Market Cap | $2.22B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $20.38 | $48.68 |
52-Week Low | $7.60 | $40.90 |
Enterprise Value | $2.29B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.
EWU, the iShares MSCI United Kingdom ETF, trades at $48.33, down 0.33% on the day, with a bullish technical signal driven by moving averages. The ETF tracks UK large-cap equities, with recent institutional activity showing mixed positions. Key support and resistance cluster around $48-$49, while RSI levels indicate neutral momentum. Geopolitical tensions and oil price volatility influence FTSE 100 performance, as highlighted in recent financial news.
The outlook for EWU is cautiously optimistic, supported by technical strength but tempered by macroeconomic risks. Opportunities include exposure to UK market resilience, while risks involve Middle East tensions and inflation concerns. Investors should weigh institutional inflows against broader market volatility for balanced positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →
